Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Drops By 41.2%

Tharimmune, Inc. (NASDAQ:THAR) was the recipient of a large decrease in short interest in the month of July. As of July 15th, there was short interest totalling 29,400 shares, a decrease of 41.2% from the June 30th total of 50,000 shares. Based on an average daily trading volume, of 50,800 shares, the days-to-cover ratio is presently 0.6 days. Currently, 2.7% of the shares of the company are short sold.

Tharimmune Price Performance

Shares of NASDAQ THAR traded up $0.15 during midday trading on Friday, hitting $3.23. 19,274 shares of the stock traded hands, compared to its average volume of 41,150. The firm has a 50-day moving average of $3.92 and a two-hundred day moving average of $5.32. Tharimmune has a one year low of $2.75 and a one year high of $142.50.

Tharimmune (NASDAQ:THAR) last released its quarterly earnings results on Thursday, May 9th. The company reported ($2.85) earnings per share for the quarter.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).